Evidence map›Paper›PMID 33647511›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Evaluation of Lumipulse® G SARS-CoV-2 antigen assay automated test for detecting SARS-CoV-2 nucleocapsid protein (NP) in nasopharyngeal swabs for community and population screening.

Alessio Gili, Riccardo Paggi, Carla Russo, Elio Cenci, Donatella Pietrella, Alessandro Graziani, Fabrizio Stracci, Antonella Mencacci

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 7 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Guideline
  2. Pooled it
  3. Pooled it
  4. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Detection of SARS-CoV2 Antigen in Wastewater Using an Automated Chemiluminescence Enzyme Immunoassay.International journal of environmental research and public health · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Prospective evaluation of the point-of-care use of a rapid antigenic SARS-CoV-2 immunochromatographic test in a paediatric emergency department.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alessio GiliPublic Health Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Riccardo PaggiMicrobiology and Clinical Microbiology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Carla RussoMicrobiology and Clinical Microbiology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Elio CenciMicrobiology and Clinical Microbiology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Donatella PietrellaMicrobiology and Clinical Microbiology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Alessandro GrazianiMicrobiology and Clinical Microbiology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Fabrizio StracciPublic Health Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Antonella MencacciMicrobiology and Clinical Microbiology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Electronic address: antonella.mencacci@unipg.it.
University of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the Lumipulse® SARS-CoV-2 antigen test with the gold standard real-time reverse transcription-polymerase chain reaction (RT-PCR) for diagnosis of SARS-CoV-2 infection and to evaluate its role in screening programs.

methodsLumipulse® SARS-CoV-2 antigen assay was compared with the gold standard RT-PCR test in a selected cohort of 226 subjects with suspected SARS-CoV-2 infection, and its accuracy was evaluated. Subsequently, the test was administered to a real-life screening cohort of 1738 cases. ROC analysis was performed to explore test features and cutoffs. All tests were performed in the regional reference laboratory in Umbria, Italy.

resultsA 42.0% positive result at RT-PCR was observed in the selected cohort. The Lumipulse® system showed 92.6% sensitivity (95% CI 85.4-97.0%) and 90.8% specificity (95% CI 84.5-95.2%) at 1.24 pg/mL optimal cutoff. In the screening cohort, characterized by 5.2% prevalence of infection, Lumipulse® assay showed 100% sensitivity (95% CI 96.0-100.0%) and 94.8% specificity (95% CI 93.6-95.8%) at 1.645 pg/mL optimal cutoff; the AUC was 97.4%, NPV was 100% (95% CI 99.8-100.0%) and PPV was 51.1% (95% CI 43.5-58.7%).

conclusionsThe Lumipulse® SARS-CoV-2 antigen assay can be safely employed in the screening strategies in small and large communities and in the general population.

Indexed as

Antigens, ViralCohort StudiesCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 Nucleic Acid TestingCOVID-19 Serological TestingHumansItalyMass ScreeningNasopharynxReal-Time Polymerase Chain ReactionSARS-CoV-2Sensitivity and SpecificityAntigens, ViralCoronavirus Nucleocapsid ProteinsAntigen NPCOVID-19DiagnosisLumipulse®SARS-CoV-2Screening

Identifiers

PMID33647511
PMCPMC7908845
OpenAlexW3135710118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.